CpG ODNs are readily recognized by TLR9 on immune cells and trigger an immunomodulatory cascade that involves antigen-presenting cells, T cells, and natural killer cells, which makes them promising for cancer immunotherapy. The gene discussed is TLR9; the disease is cancer.